Investor Relations
"...treating the cause rather than the symptom."
Ben Change, CEO
We strive to change the standard of care and serve patients who suffer from disease brought on by inflammation. accelerating advancements in science and medicine.
Our goal is to offer better care and first-line targeted therapies in the areas of hematology, oncology, neurology, and lung disorders.
Our goal is to offer better care and first-line targeted therapies in the areas of hematology, oncology, neurology, and lung disorders.
Parkinson’s disease (PD)
HL: The market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 16%
AML: The AML global market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14%.
PD: The global PD therapeutics market was valued at US$ 2.18 Billion in 2016 and is projected to register a CAGR of more than 10.9% from 2017 to 2025
Stroke: The Global Stroke Diagnostics and Therapeutics market is expected to reach $49,698.98 million by 2026 growing at a CAGR of 7.9% during 2018 to 2026.